Bluebird Bio, Inc. Announces Board and Committee Appointments
October 05, 2021 at 09:06 pm
Share
Effective September 29, 2021, the board of directors of bluebird bio, Inc. appointed Sarah Glickman to the Board as a Class II director and Najoh Tita-Reid to the Board as a Class III director, and increased the size of the board to eleven. Ms. Tita-Reid has been appointed as a member of the Nominating and Corporate Governance Committee and the Compensation Committee of the Board, effective upon the consummation of the planned separation of the Company's oncology programs and portfolio from its severe genetic disease programs and portfolio through the spinoff of 2seventy bio, Inc. as an independent, publicly-traded Delaware corporation (the Separation). Glickman has not been appointed to any committees of the Board. Since September 2020, Sarah Glickman has served as the Chief Financial Officer for Criteo. Since April 2021, Najoh Tita-Reid has served as Global Chief Marketing Officer for Logitech.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).